Cibus (CBUS) Gains from Investment Securities (2022 - 2025)
Cibus (CBUS) posted Gains from Investment Securities of $20000.0 for Q4 2025, up 266.67% sequentially from -$12000.0 in Q3 2025, and up 105.09% YoY from $9751.9 in Q4 2024.
Cibus (CBUS) Gains from Investment Securities (2022 - 2025) Analysis & Trends
Cibus has reported Gains from Investment Securities for 4 years, with the latest figure at $20000.0 in Q4 2025.
- Quarterly Gains from Investment Securities rose 105.09% year-over-year to $20000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$447000.0 (up 95.19% YoY) and the FY2025 annual result came in at -$447000.0, up 95.19% from the prior year.
- Gains from Investment Securities advanced to $20000.0 in Q4 2025 per CBUS's latest filing, from -$12000.0 in the prior quarter.
- Over five years, Gains from Investment Securities peaked at $850000.0 in Q3 2023 and troughed at -$7.7 million in Q3 2024.
- A 4-year average of -$644142.9 and a median of -$102500.0 in 2022 frame the typical range for Gains from Investment Securities.
- The sharpest annual moves came in 2023 and 2024: Gains from Investment Securities soared 397.2% in 2023, then slumped 1008.0% in 2024.
- Over 4 years, Gains from Investment Securities stood at -$111000.0 in 2022, then increased by 15.32% to -$94000.0 in 2023, then tumbled by 318.09% to -$393000.0 in 2024, then soared by 105.09% to $20000.0 in 2025.
- According to Business Quant data, Gains from Investment Securities over the past three periods registered $20000.0, -$12000.0, and $7000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Cibus | 129.72 Mn | 109.29 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 20,000.00 |
| Dec 31, 2025 | 20,000.00 |
| Sep 30, 2025 | -12,000.00 |
| Sep 30, 2025 | -12,000.00 |
| Jun 30, 2025 | 7,000.00 |
| Jun 30, 2025 | 7,000.00 |
| Mar 31, 2025 | -462,000.00 |
| Mar 31, 2025 | -462,000.00 |
| Dec 31, 2024 | -393,000.00 |
| Dec 31, 2024 | -393,000.00 |
| Sep 30, 2024 | -7.72 Mn |
| Sep 30, 2024 | -7.72 Mn |
| Jun 30, 2024 | -1.58 Mn |
| Jun 30, 2024 | -1.58 Mn |
| Mar 31, 2024 | 390,000.00 |
| Mar 31, 2024 | 390,000.00 |
| Dec 31, 2023 | -94,000.00 |
| Dec 31, 2023 | -94,000.00 |
| Sep 30, 2023 | 850,000.00 |
| Sep 30, 2023 | 850,000.00 |